SCHEMBL217518

SCHEMBL217518

Oc1ccc2c(c1)CC=C2

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DRD2 P14416 3/20 0.36
DRD4 P21917 1/20 0.36
ESR1 P03372 7/20 0.36
ESR2 Q92731 6/20 0.36
HSD17B10 Q99714 1/20 0.36
PTPRC P08575 1/20 0.35
DRD3 P35462 2/20 0.34
MAOA P21397 1/20 0.34
MAOB P27338 1/20 0.34
PRKCI P41743 1/20 0.34
DRD1 P21728 1/20 0.34
DRD5 P21918 1/20 0.34
OPRK1 P41145 1/20 0.33
CA2 P00918 2/20 0.32
CA5A P35218 1/20 0.32
PBRM1 Q86U86 1/20 0.32
CA12 O43570 1/20 0.32
CA1 P00915 1/20 0.32
CA7 P43166 1/20 0.32
CA9 Q16790 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29634416 1.00 DRD2 (0.36) DRD2DRD4ESR1ESR2HSD17B10
SCHEMBL3755892 0.90 ESR1 (0.38) DRD2DRD4ESR1ESR2HSD17B10
SCHEMBL9995642 0.85 DRD2 (0.35) DRD2DRD4ESR1ESR2HSD17B10
SCHEMBL28861019 0.84 ESR1 (0.43) ESR1ESR2
SCHEMBL275808 0.82 PBRM1 (0.36) DRD2DRD4ESR1ESR2HSD17B10
SCHEMBL1476906 0.78 DRD2 (0.38) DRD2DRD4ESR1ESR2HSD17B10
SCHEMBL3861910 0.78 DRD2 (0.36) DRD2DRD4ESR1ESR2HSD17B10
SCHEMBL1896564 0.77 HTR2C (0.38) DRD4
SCHEMBL31513977 0.77 HTR2C (0.38) DRD4
Indene SCHEMBL16297370 0.76 CA1 (0.47) ESR1ESR2HSD17B10CA2CA5A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 208 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250127694-A1 FRAGRANCE COMPOSITIONS AND USES THEREOF COTY INC. 2025-04-24 US disclosed
CN-114127038-B Isomerization process for products obtained from the condensation reaction of ketones and phenols to bisphenols PTT全球化学公共有限公司 2025-01-03 CN disclosed
US-12037346-B2 Amino-substituted heteroaryls for treating cancers with EGFR mutations NUVALENT, INC. (US) 2024-07-16 US disclosed
US-20230159766-A1 CONDUCTIVE POLYMER COMPOSITION, SUBSTRATE, AND METHOD FOR PRODUCING SUBSTRATE SHIN-ETSU CHEMICAL CO., LTD. (JP) 2023-05-25 US disclosed
CN-106232794-B Fabric care compositions comprising polyurethane, polyurea and/or polyurethaneurea polymers 宝洁公司 2023-04-21 CN disclosed
US-11573491-B2 Negative tone photosensitive composition for EUV light, pattern forming method, and method for manufacturing electronic device FUJIFILM CORPORATION (JP) 2023-02-07 US disclosed
CN-114127038-A Process for isomerizing products obtained from the condensation of ketones and phenols to produce bisphenols PTT全球化学公共有限公司 2022-03-01 CN disclosed
US-20210011380-A1 NEGATIVE TONE PHOTOSENSITIVE COMPOSITION FOR EUV LIGHT, PATTERN FORMING METHOD, AND METHOD FOR MANUFACTURING ELECTRONIC DEVICE FUJIFILM CORPORATION (JP) 2021-01-14 US disclosed
CN-112105654-A Curable resin mixture, curable resin composition, and cured product thereof 日本化药株式会社 2020-12-18 CN disclosed
US-20200259094-A1 CONDUCTIVE POLYMER COMPOSITE AND CONDUCTIVE POLYMER COMPOSITION SHIN-ETSU CHEMICAL CO., LTD. (JP) 2020-08-13 US disclosed
WO-2006062240-A1 3-ETHYLIDENEHYDRAZINO SUBSTITUTED HETEROCYCLIC COMPOUNDS AS THROMBOPOIETIN RECEPTOR ACTIVATORS NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2006-06-15 WO disclosed
US-20060094694-A1 Heterocyclic compounds and thrombopoietin receptor activators NISSAN CHEMICAL INDUSTRIES LIMITED (JP) 2006-05-04 US disclosed
EP-1636192-A1 3-ALKYLIDENEHYDRAZINO SUBSTITUTED HETEROARYL COMPOUNDS AS THROMBOPOIETIN RECEPTOR ACTIVATORS Nissan Chemical Industries, Ltd. (JP) 2006-03-22 EP disclosed
US-20060014106-A1 Photoresist undercoat-forming material and patterning process SHIN-ETSU CHEMICAL CO., LTD. 2006-01-19 US disclosed
WO-2004108683-A1 3-ALKYLIDENEHYDRAZINO SUBSTITUTED HETEROARYL COMPOUNDS AS THROMBOPOIETIN RECEPTOR ACTIVATORS NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2004-12-16 WO disclosed
US-4806555-A CARDIAC ARRHYTHMIA INHIBITOR A. H. ROBINS COMPANY, INCORPORATED (US) 1989-02-21 US disclosed
US-4609735-A HYPOTENSIVE, ANTIARRHYTHMIA A. H. ROBINS COMPANY, INC. (US) 1986-09-02 US disclosed
US-4538001-A FROM 1-ARYLOXY-4-CHLORO-2-BUTANOL INTERMEDIATES; LOCAL ANESTHETICS, ANTIARRHYTHMICS, HYPOTENSIVES, BETA-ADRENERGIC BLOCKERS A. H. ROBINS COMPANY, INC. (US) 1985-08-27 US disclosed
US-4463190-A FOR USE AS ADRENERGIC BLOCKING, HYPOTENSIVE, AND HYPOTENSIVE AGENTS; LOCAL ANESTHETIC A. H. ROBINS COMPANY, INC. (US) 1984-07-31 US disclosed
US-4379167-A 1-Aryloxy-4-amino-2-butanols and the pharmaceutical use thereof A. H. ROBINS COMPANY, INC. (US) 1983-04-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12037346-B2 Amino-substituted heteroaryls for treating cancers with EGFR mutations EGFR, ERBB2, ERBB3 DRD2 4326/4885DRD4 4369/4885ESR1 306/4885
US-20060094694-A1 Heterocyclic compounds and thrombopoietin receptor activators NR2C2, ROR1, NR0B2 DRD2 1694/4885DRD4 1903/4885ESR1 96/4885
US-20250127694-A1 FRAGRANCE COMPOSITIONS AND USES THEREOF TRPA1, TRPV1, NAA40 DRD2 2569/4885DRD4 2954/4885ESR1 3601/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.